M3 Group extends reach in Iberian and Latin American markets with partnership

Share this article:
Aki Tomaru
Aki Tomaru

MDLinx owner M3 Group is partnering with Argentine online CME firm Medcenter on a content-sharing deal that will expand its in-language reach to Spain, Portugal and Latin America.

Medcenter will join M3's Networks in Health, an “international alliance of online physician communities that provides pharmaceutical, medical device and other healthcare companies services for reaching and engaging doctors across Europe, the Americas and Asia.”

“We're trying to be global,” said Aki Tomaru, CEO of M3 USA. Tomaru said that while M3's Doctors.net.uk runs pan-European campaigns, pharmas are increasingly shopping for broader buys that hopscotch across global markets.

“They want to cherry-pick the countries,” said Tomaru. Until now, he added, that meant either partnering with a different in-culture shop in each country or distributing their content in English through WebMD's Medscape (with which Medcenter had a previous affiliation). “The willingness of most physicians in non-English-speaking countries to spend time on English language materials is limited,” said Tomaru.

Medcenter boasts a network of 480,000 physicians. M3, a Sony-owned Japanese conglomerate whose portfolio includes M3.com in Japan, US-based MDLinx and UK-based Doctors.net.uk, claims more than a million physician members worldwide.
Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.